BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28627804)

  • 1. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
    Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of
    Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
    Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
    Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
    Lehtisalo M; Taskinen S; Tarkiainen EK; Neuvonen M; Viinamäki J; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Backman JT; Tornio A; Niemi M
    Br J Clin Pharmacol; 2023 Jan; 89(1):242-252. PubMed ID: 35942816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.
    Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S
    Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
    Khine H; Yuet WC; Adams-Huet B; Ahmad Z
    Am Heart J; 2016 Sep; 179():1-9. PubMed ID: 27595674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
    Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
    Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
    Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
    Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
    Couvert P; Giral P; Dejager S; Gu J; Huby T; Chapman MJ; Bruckert E; Carrié A
    Pharmacogenomics; 2008 Sep; 9(9):1217-27. PubMed ID: 18781850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.
    Kim KA; Joo HJ; Lee HM; Park JY
    Mol Biol Rep; 2013 Jul; 40(7):4211-7. PubMed ID: 23666051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on efflux and uptake transporters as determinants of statin response.
    Rocha KCE; Pereira BMV; Rodrigues AC
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
    Hu M; Tomlinson B
    Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.